tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GTHX Stock Latest News

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Press ReleasesG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
3d ago
GTHX
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
PremiumPress Releases
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
16d ago
GTHX
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18d ago
GTHX
G1 Therapeutics Executives Take Pay Cut for Cost Management
PremiumCompany Announcements
G1 Therapeutics Executives Take Pay Cut for Cost Management
28d ago
8K
GTHX
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
GTHX
G1 Therapeutics sees FY24 COSELA revenue $60M-$70M
PremiumThe FlyG1 Therapeutics sees FY24 COSELA revenue $60M-$70M
2M ago
GTHX
G1 Therapeutics reports Q4 EPS (21c), consensus (27c)
PremiumThe Fly
G1 Therapeutics reports Q4 EPS (21c), consensus (27c)
2M ago
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
PremiumPress Releases
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2M ago
GTHX
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2M ago
GTHX
Is GTHX a Buy, Before Earnings?
PremiumPre-Earnings
Is GTHX a Buy, Before Earnings?
2M ago
GTHX
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
VIR
ADIL
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ACST
ADIL
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
PremiumPress ReleasesG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
2M ago
GTHX
G1 Therapeutics price target lowered to $12 from $14 at Needham
PremiumThe Fly
G1 Therapeutics price target lowered to $12 from $14 at Needham
2M ago
GTHX
G1 Therapeutics tumbles after DMC recommends Phase 3 trial continues
PremiumThe Fly
G1 Therapeutics tumbles after DMC recommends Phase 3 trial continues
2M ago
GTHX
G1 Therapeutics Advances Phase 3 Breast Cancer Trial
PremiumCompany Announcements
G1 Therapeutics Advances Phase 3 Breast Cancer Trial
2M ago
8K
GTHX
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
PremiumPress Releases
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
2M ago
GTHX
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
3M ago
GTHX
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
4M ago
GTHX
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4M ago
GTHX
G1 Therapeutics presents post hoc analyses on trilaciclib with chemotherapy
PremiumThe Fly
G1 Therapeutics presents post hoc analyses on trilaciclib with chemotherapy
5M ago
GTHX
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
PremiumPress Releases
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
5M ago
GTHX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >